Burning Rock Biotech (BNR) Current Deferred Revenue (2021 - 2023)

Burning Rock Biotech has reported Current Deferred Revenue over the past 3 years, most recently at $18.1 million for Q4 2023.

  • Quarterly results put Current Deferred Revenue at $18.1 million for Q4 2023, down 12.66% from a year ago — trailing twelve months through Dec 2023 was $18.1 million (down 12.66% YoY), and the annual figure for FY2023 was $18.4 million, down 16.38%.
  • Current Deferred Revenue for Q4 2023 was $18.1 million at Burning Rock Biotech, down from $20.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BNR hit a ceiling of $22.3 million in Q4 2021 and a floor of $18.1 million in Q4 2023.
  • Median Current Deferred Revenue over the past 3 years was $20.8 million (2022), compared with a mean of $20.4 million.
  • Biggest five-year swings in Current Deferred Revenue: fell 7.11% in 2022 and later fell 12.66% in 2023.
  • Burning Rock Biotech's Current Deferred Revenue stood at $22.3 million in 2021, then fell by 7.11% to $20.8 million in 2022, then dropped by 12.66% to $18.1 million in 2023.
  • The last three reported values for Current Deferred Revenue were $18.1 million (Q4 2023), $20.8 million (Q4 2022), and $22.3 million (Q4 2021) per Business Quant data.